Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 9(7): e103254, 2014.
Article in English | MEDLINE | ID: mdl-25050704

ABSTRACT

Graft versus host disease (GvHD) is one of the main complications after hematological stem cell transplantation (HSCT). CAMPATH-1H is used in the pre-transplant conditioning regimen to effectively reduce GvHD by targeting CD52 antigens on T cells resulting in their depletion. Information regarding CD52 expression and the effects of CAMPATH-1H on immune cells is scant and limited to peripheral blood (PB) T and B cells. To date, the effects of CAMPATH-1H on cord blood (CB) cells has not been studied. Here we aimed to analyze CD52 expression and the effects of CAMPATH-1H on fresh or frozen, resting or activated, PB mononuclear cells (PBMC) and CB mononuclear cells (CBMC). In resting state, CD52 expression was higher in CB than PB T cell subsets (653.66 ± 26.68 vs 453.32 ± 19.2) and B cells (622.2±20.65 vs 612.0 ± 9.101) except for natural killer (NK) cells where CD52 levels were higher in PB (421.0 ± 9.857) than CB (334.3 ± 9.559). In contrast, CD52 levels were comparable across all cell types after activation. CAMPATH-1H depleted resting cells more effectively than activated cells with approximately 80-95% of apoptosis observed with low levels of necrosis. There was no direct correlation between cell surface CD52 density and depleting effects of CAMPATH-1H. In addition, no difference in cell viability was noted when different concentrations of CAMPATH-1H were used. CD52 was not expressed on HSC but began to be expressed as the cells differentiate, implying that CAMPATH-1H could potentially affect HSC differentiation and proliferation. Our study provides insightful information, which contributes to the better understanding in the use of CAMPATH-1H as part of the conditioning regime in HSCT.


Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antigens, CD/analysis , Antigens, Neoplasm/analysis , Antineoplastic Agents/pharmacology , Cell Survival/drug effects , Glycoproteins/analysis , Leukocytes, Mononuclear/drug effects , Alemtuzumab , Antigens, CD/immunology , Antigens, Neoplasm/immunology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , CD52 Antigen , Cell Separation , Glycoproteins/immunology , Humans , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Leukocytes, Mononuclear/immunology
2.
Cytotherapy ; 16(10): 1409-18, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24969967

ABSTRACT

BACKGROUND AIMS: Graft-versus-host disease remains a major cause of death after hematopoietic stem cell transplantation. Cyclosporine (CsA) and mycophenolate mofetil (MMF) have been successfully used alone or in combination as prophylaxis for graft-versus-host disease. Although the effects of these drugs on T cells have been studied, little is known about the effects of both drugs on natural killer (NK) cells. We examined if the sensitivity of umbilical cord blood (CB) NK cells to MMF and/or CsA differs from their adult counterparts. METHODS: An approach that was based on flow cytometry and real-time polymerase chain reaction was used to assess the effects of MMF, CsA and the combination of both drugs on the viability, activation, proliferation and cytotoxicity of peripheral blood (PB) and CB NK cells after culture with interleukin-2. RESULTS: MMF alone or together with CsA induced cell death of CB NK cells but not of PB NK cells. MMF and CsA had differential effects on NK cell activation but significantly reduced proliferation of CB NK cells. MMF reduced perforin expression by PB NK cells, whereas CsA alone or together with MMF drastically decreased degranulation of CB and PB NK cells. However, neither affected cytokine secretion by PB and CB NK cells. CONCLUSIONS: This study showed that CB NK cells were more sensitive to MMF and CsA than were PB NK cells. MMF and CsA had significant effects on NK cells that could jeopardize the beneficial effects of NK cells after hematopoietic stem cell transplantation.


Subject(s)
Cyclosporine/pharmacology , Fetal Blood/cytology , Killer Cells, Natural/drug effects , Lymphocyte Activation/drug effects , Mycophenolic Acid/analogs & derivatives , Adult , Cells, Cultured , Female , Fetal Blood/immunology , Graft vs Host Disease/immunology , Hematopoietic Stem Cell Transplantation , Humans , Infant, Newborn , Interleukin-2/pharmacology , Killer Cells, Natural/immunology , Lymphocyte Activation/immunology , Mycophenolic Acid/pharmacology , Pregnancy
3.
Transplantation ; 97(8): 870-8, 2014 Apr 27.
Article in English | MEDLINE | ID: mdl-24670298

ABSTRACT

BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is a common treatment for hematological diseases. Cord blood (CB) is increasingly used as a source of stem cells for HSCT. Prophylactic drugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), are often used together after HSCT to prevent graft-versus-host disease (GvHD), but so far little is known about their effects on CB mononuclear cells (CBMCs). As CB and peripheral blood (PB) have different cell compositions and characteristics, it was hypothesized that MMF and CsA might have different effects on CB and PB T cells. METHODS: Using a combination of flow cytometry, ELISA, and quantitative PCR, the effects of MMF, CsA, and the combination of both drugs were studied on resting and activated CBMCs and peripheral blood mononuclear cells. RESULTS: MMF had a stronger effect on activated PB T cells than on activated CB T cells, which was consistent with the lower level of IMPDH2 mRNA expressed by PB T cells. Interestingly, only MMF could preserve the activated CB regulatory T-cell population. Activated CB T cells were more sensitive to CsA than activated PB T cells, which might be explained by the lower NFATc1 expression and cytokine secretion. These results may explain the lower GvHD incidence observed in recipients of CB transplants. CONCLUSION: This study provides valuable insight into the effects of immunosuppressive drugs used after HSCT on resting and activated T-cell subsets from PB but especially from CB.


Subject(s)
Cord Blood Stem Cell Transplantation , Graft vs Host Disease/prevention & control , Mycophenolic Acid/analogs & derivatives , T-Lymphocytes, Regulatory/drug effects , Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/metabolism , Cell Death/drug effects , Cell Proliferation/drug effects , Cyclosporine/pharmacology , Cytokines/metabolism , Fetal Blood/cytology , Fetal Blood/immunology , Graft vs Host Disease/drug therapy , Graft vs Host Disease/immunology , Humans , Immunosuppressive Agents/pharmacology , In Vitro Techniques , Interleukin-2 Receptor alpha Subunit/metabolism , Lectins, C-Type/metabolism , Leukocyte Common Antigens/metabolism , Lymphocyte Activation/drug effects , Mycophenolic Acid/pharmacology , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...